Xilio Therapeutics (XLO) - Company Gross Revenue

Xilio - graphic logo of issuer XLO

Xilio Therapeutics, Inc. (XLO) combines the development of specific cytokines with the automation of clinical data analysis via software robots. The company's sales history demonstrates the dynamics of commercial operations, where the value of 0.06 represents the current metric level. However, the lack of recurring revenue and low cash flows are due to the stage of developing targeted immunotherapeutic drugs prior to their official regulatory approval.

XLO - Xilio Therapeutics Revenue and Sales Volume over the range 07/04/2022 - 11/18/2026

Analytical breakdowns for xiliotx.com (XLO)

- market capitalization indicators:
General company analysis:Xilio Therapeutics, XLO
Original product of Xilio Therapeutics, Inc.

Investment analysis of Xilio Therapeutics, Inc. (XLO) requires a deep dive into cash flows to assess business sustainability. This indicator measures daily revenue, reflecting the market quality of asset management and the risk of capital losses. The volume dynamics of Xilio Therapeutics, Inc. (XLO) products allow for an assessment of the commercial success of its proprietary cytokine platform amidst fierce competition with Big Pharma behemoths. Steady growth in this metric confirms the effectiveness of clinical trials and the fundamental value of the issuer.

Key competitors

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Total Revenue|OSTX: Company Sales|Company Sales Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Revenue|ANL: Company Total Sales|VERU (Veru Corporation) - Revenue and Sales Volume|Company Total Revenue Tempest Therapeutics, Inc. TPST|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue